cure in patients with chronic hepatitis B (CHB) infection, announced that review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study evaluating the therapeutic vaccine CLB-4000 ( ACTRN12625000250437 and ACTRN12625000204448  CLB-4000 is a bivalent subunit therapeutic vaccine comprised of CLB-405 and CLB-505 proteins, adjuvanted with TQL-1055. CLB-405 and CLB-505 are variants of HBsAg designed to over-represent clearance profile epitopes identified from functional cure patients. TQL-1055 is a novel, rationally designed, semi-synthetic saponin adjuvant licensed from Adjuvance Technologies, Inc. The CLB-4000-1-001 Phase 1b is an open label multicenter, multiple-dose study designed to assess the safety and tolerability of repeated intramuscular (IM) administration of CLB-4000 (fixed antigen amounts of 250 μg CLB-405 and 250 μg CLB-505, adjuvanted with multiple dose levels of TQL-1055), in noncirrhotic adults with CHB taking a stable dose of a standard of care NUC for viral suppression. To further boost the immune and antiviral responses, additional cohorts will evaluate CLB-4000 with Peg-IFNα-2a. The objectives of the study are safety and tolerability of CLB-4000 with or without Peg-IFNα-2a. Additional objectives include evaluation of antiviral activities and immunological responses. Results are expected on a rolling basis starting 2H 2026.  “It is very exciting to evaluate our promising therapeutic vaccine, CLB-4000 in first in human trials in CHB patients. We look forward to sharing emerging clinical data with the Hepatitis B community as it becomes available” said Aileen Rubio, PhD, CEO for the company. “CHB infection remains a substantial global health care problem with a continued need for safe and effective therapies. We believe that CLB-4000 could become an important component of evolving CHB treatment regimens.”  About Hepatitis B  The World Health Organization defines hepatitis B as a “potentially life-threatening liver infection caused by Hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.” Approximately 2 billion people are infected with HBV and ~250 million living with CHB. Viral hepatitis is the 7 th ranked cause of human death and liver cancer is the 3 rd most common cause of cancer related death globally.  About ClearB Therapeutics  ClearB Therapeutics was co-founded in 2017 with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop immune based therapies designed to drive functional cure of hepatitis B infection. The work is grounded in proprietary insights derived from rare-event infection resolution in patients who suffer from CHB. For more information, please visit https://clearbtherapeutics.com/  About TQL-1055  TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically-advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS-21 and has shown favorable tolerability in a Phase 1 clinical trial.

ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection

CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that the company has licensed TQL-1055 from Adjuvance Technologies, Inc. TQL-1055 is a novel saponin-based adjuvant that will be combined with ClearB’s proprietary variants of HBsAg, CLB-405 and CLB-505. Pre-clinical data related to this therapeutic vaccine combination will be presented as posters at the American Association f

ClearB Therapeutics Announces License and Collaboration With Adjuvance Technologies to Access a Novel Saponin Adjuvant, TQL-1055, and Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at AASLD 2024

Search jobs
03-May-2024
Vaccine Adjuvants Market Size to Surpass USD 1.5 Billion by 2032, Exhibiting a CAGR of 4%
Allied Market Research published a report, titled, “ Vaccine Adjuvants Market by Product Type (Immunostimulants and Vehicles & Mucosal Adjuvants), Disease (Infectious Diseases and Cancer), and Application (Research and Commercial): Global Opportunity Analysis and Industry Forecast, 2023–2032”. According to the report, the vaccine adjuvants market was valued at $1 billion in 2022 and is estimated to reach $1.5 billion by 2032, exhibiting a CAGR of 4% from 2023 to 2032. Prime Determinants of Growth:
Growing healthcare infrastructure, rise in prevalence of disease conditions that require effective treatment, and growing awareness regarding the use of vaccine adjuvants in vaccine for research as well as commercial utilization are the factors that drive the growth of the global vaccine adjuvants market. However, high development cost and stringent regulatory requirements hinder the market growth. On the contrary, a rise in healthcare expansion and the growing infectious disease load are expected to offer remunerative opportunities for the vaccine adjuvants market during the forecast period. Request Sample of the Report on Vaccine Adjuvants Market Forecast 2032 https://www.alliedmarketresearch.com/request-sample/1666
Recession Scenario
During a recession, the impact on the healthcare industry, including vaccine adjuvants, has significantly affected the market in a moderately negative stance. The economic downturns may hinder technology investment. However, the growing infectious disease load among the global population and the rise in commercial as well as research utilization of adjuvants can drive interest in the vaccine adjuvants market. The Immunostimulants Segment To Maintain Its Lead Position During The Forecast Period
Based on type, the immunostimulants segment dominated the market in 2022, accounting for more than half of the global vaccine adjuvants market. This is attributed to wide availability of vaccine adjuvants in the commercially available products. Also to boost the body’s immune response to vaccines, immunostimulants are preferred, and development of innovative drug delivery systems further drives the segment growth. The Infectious Disease Segment To Maintain Its Lead Position During The Forecast Period
Based on disease, the infectious disease segment dominated the market in 2022, accounting for more than three-fourths of the global vaccine adjuvants market, as numerous people are affected by infectious diseases, which frequently have high incidence rates. As a result, there is a sizable market for adjuvanted vaccines against infectious pathogens. Adjuvants are essential for increasing the vaccinations’ effectiveness and increasing their desirability for research and development as well as for commercialization. Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/1666
The Commercial Segment To Maintain Its Lead Position During The Forecast Period
Based on application, the commercial segment dominated the market in 2022, accounting almost three-fourths of the global vaccine adjuvants market, mainly due to the availability of various commercially available vaccines for varied applications, and also the segment is anticipated to grow with the fastest CAGR owing to high prevalence of infectious diseases, thus further boosting the growth of the segment. North America To Maintain Its Dominance By 2032
Based on region, North America held the highest market share in terms of revenue in 2022, accounting for almost two-fourths of the global vaccine adjuvants market, owing to presence of well-developed healthcare industry. In addition, the growing focus of key players on R&D contributes to the formulation of innovative vaccine adjuvants; thereby driving the market growth in the region. However, the Asia-Pacific segment is projected to register highest CAGR of 4.8% during the forecast period owing to increase in the number of infectious diseases leading to a surge in the patient populations and improving healthcare infrastructure in the region for research and development purposes. For Procurement Information – https://www.alliedmarketresearch.com/purchase-enquiry/1666
Aurorium
The report provides a detailed analysis of these key players of the global vaccine adjuvants market. These players have adopted different strategy such as partnership and business expansion to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Editor Details

Vaccine Adjuvants Market Size to Surpass USD 1.5 Billion by 2032, Exhibiting a CAGR of 4%

Opportunity for Innovation Within the Vaccine Adjuvants Market Remains Strong
The opportunity for innovation within the  global vaccine adjuvants market  remains strong. As time progresses, the technology used in the manufacturing and development of vaccines is improved. This will lead to improvements in the manufacturing processes of vaccines that could save costs. Similarly, it allows for innovative vaccine platforms to be researched. This could lead to better vaccines that give a stronger efficacy, or new targets for vaccines could be found. This will all contribute to developing the vaccine adjuvants market. Indian Vaccine Adjuvants Market to Witness Highest Growth Rate
India is another extremely promising market in the developing world. India is the second largest populous nation in the world with approximately 1.3 billion people in 2020. The Indian vaccine adjuvants market holds great potential due to its sheer population and extremely high birth rates that feeds the  vaccine adjuvants demand . However, due to structural and economic barriers, a large proportion of the society is unable to access the vaccines. An estimated 2.5 million lives are lost each year in India due to diseases that are apparently avoidable through vaccines. The low vaccine coverage rates are due to the low per capita vaccine expenditure reported, which in turn results in an unequal market with low access to immunization. According to Visiongain analysis, continuous improvement in healthcare facilities coupled with rising R&D activities by government and major companies are anticipated to fuel the regional vaccine adjuvants market growth. Competitive Landscape
According to Visiongain analysis, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global vaccine adjuvants market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the vaccine adjuvants market. Some of the leading companies profiled in the report include: GSK, CSL, Agenus, Adjuvance, Novavax, SPI Pharma, Invivogen, Avanti Polar Lipids, Seppic, Croda, MVP Laboratories, OZ Biosciences, and Dynavax. Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. To access the data contained in this document please email  contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the vaccine adjuvants market and leading companies . You will find data, trends and predictions. Find more Visiongain research reports on Therapeutic Drugs Sector  click on the following links:
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of  market research reports  which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs. Contact:

Vaccine Adjuvants Market Report Up to 2031: Visiongain Research Inc

The Global Structural Biology & Molecular Modeling Techniques Market size was estimated at USD 5,713.68 million in 2020, is expected to reach USD 6,731.28 million in 2021, and is projected to grow at a CAGR of 18.17% to reach USD 18,391.59 million by 2027. Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period. Market Segmentation & Coverage:
This research report categorizes the Structural Biology & Molecular Modeling Techniques to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Tools, the market was studied across Databases, SaaS & standalone modeling, and Visualization & analysis. The SaaS & standalone modeling is further studied across Ab Initio, Homology modeling, Hybrid, Molecular dynamics, and Threading. Based on Application, the market was studied across Drug Development and Drug Discovery. Based on Region, the market was studied across the Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Structural Biology & Molecular Modeling Techniques Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Structural Biology & Molecular Modeling Techniques Market, including Acellera Ltd., Adjuvance Technologies, Inc., Agenus Inc., Agile Molecule, Agilent Technologies, Inc., Avanti Polar Lipid, BioInformatics, LLC, Biomax Informatics AG, Brenntag SE, Bruker Daltonics Inc., Chemical Computing Group, CLC bio, Dassault Systemes SE, Illumina, Inc., InvivozGen, Novartis International AG, Novavax, Inc., SPI Pharma, and Thermo Fisher Scientific, Inc. The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Structural Biology & Molecular Modeling Techniques Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Structural Biology & Molecular Modeling Techniques Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Structural Biology & Molecular Modeling Techniques Market? 4. What is the competitive strategic window for opportunities in the Global Structural Biology & Molecular Modeling Techniques Market? 5. What are the technology trends and regulatory frameworks in the Global Structural Biology & Molecular Modeling Techniques Market? 6. What is the market share of the leading vendors in the Global Structural Biology & Molecular Modeling Techniques Market? 7. What modes and strategic moves are considered suitable for entering the Global Structural Biology & Molecular Modeling Techniques Market? Key Topics Covered:

Outlook on the Structural Biology & Molecular Modeling Techniques Global Market to 2027 - Featuring Acellera, Agenus and Illumina Among Others

Adjuvance Technologies

Memorial Sloan Kettering Cancer Center

Series A

Adjuvance Technologies operates as a privately owned biopharmaceutical company dedicated to vaccine adjuvant design and manufacturing. The company is commercializing synthetic methods of producing the adjuvant molecule and developing a portfolio of vaccine adjuvants. It was founded in 2013 and is based in Lincoln, Nebraska.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
8/29/2019	Series A	$20M	5Y Capital, and Invest Nebraska	$XXM	0 FY undefined	3
9/22/2015	Debt	$XXM	Subscribe to see more	$XXM	0 FY undefined	10

Date	8/29/2019	9/22/2015
Round	Series A	Debt
Amount	$20M	$XXM
Investors	5Y Capital, and Invest Nebraska	Subscribe to see more
Valuation	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined
Sources	3	10

First funding	Last Funding	Investor	Rounds	Board Seats	Type	Location
8/29/2019	8/29/2019	Invest Nebraska	1 Series A		Venture Capital	Nebraska
00/00/0000	00/00/0000	5Y Capital	Subscribe to see more		Venture Capital	China

First funding	8/29/2019	00/00/0000
Last Funding	8/29/2019	00/00/0000
Investor	Invest Nebraska	5Y Capital
Rounds	1 Series A	Subscribe to see more
Board Seats
Type	Venture Capital	Venture Capital
Location	Nebraska	China

How VCs Use CB Insights

Professional Services

Platform Overview

Adjuvance Technologies

Total Raised

Investors Count

Funding, Valuation & Revenue

Adjuvance Technologies Investors